Abbreviations used: CIA, collagen-induced arthritis; CNS, central nervous system; DLN, draining LN; EAE, experimental autoimmune encephalomyelitis; MOG, myelin-oligodendrocyte glycoprotein peptide; PLP, proteolipid protein peptide.

IL-23 plays a pivotal role in the establishment and maintenance of organ-specific inflammatory autoimmune diseases. In particular, we have demonstrated that IL-23--deficient (IL-23p19^−/−^) mice are resistant to experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis (CIA; references [@bib1], [@bib2]), and IBD (unpublished data), highlighting an important role of this cytokine in autoimmune pathogenesis. Although IL-23 shares a common p40 subunit with IL-12 ([@bib3]), these cytokines have divergent activities. IL-12 is an important factor for the differentiation of naive T cells into IFN-γ--producing Th1 cells, is essential for antimicrobial responses ([@bib4], [@bib5]), and serves as a suppressor of human B cell tumors ([@bib6]). IL-23--deficient mice display normal immune responses to acute microbial infections such as *Toxoplasma gondii*. ([@bib7]). However, IFN-γ^−/−^ ([@bib8]), IFN-γR^−/−^ ([@bib9]), IL-12Rβ2^−/−^ ([@bib10]), and IL-12p35^−/−^ mice ([@bib11], [@bib12]), which all lack critical components of the Th1--IFN-γ pathway, are highly susceptible to inflammatory autoimmune diseases, questioning whether IFN-γ--producing T cells have an essential role in autoimmune pathogenesis. In this paper, we demonstrate that IL-23 promotes a T cell population characterized by the production of IL-17, IL-17F, TNF, IL-6, and other additional novel factors. Upon adoptive transfer to naive recipient mice, this IL-23--dependent T cell subset invades the target organ and can promote the development of organ-specific autoimmune inflammation.

Results
=======

Differential cytokine expression of central nervous system (CNS)--infiltrating CD4^+^ T cells
---------------------------------------------------------------------------------------------

To study the role of IL-23 in autoimmune inflammatory disease pathogenesis, we used a CNS autoimmune model because the target organ is normally free of activated macrophages and CD4^+^ T cells ([@bib13]); therefore, we can monitor the infiltration of inflammatory cells into the CNS during disease development. Just before disease onset, myelin-oligodendrocyte glycoprotein peptide (MOG)~35-55~--primed WT mice exhibited a large influx of CNS-invading immune cells ([Fig. 1](#fig1){ref-type="fig"} A). Surprisingly, although IL-23--deficient mice (IL-23p19^−/−^) were completely EAE resistant, comparable numbers of immune cells invaded the CNS ([Fig. 1](#fig1){ref-type="fig"} A). In vitro stimulation of the CNS-invading CD4^+^ cells showed equivalent number of MOG-specific, IFN-γ--producing cells in both the IL-23p19^−/−^ and WT mice ([Fig. 1](#fig1){ref-type="fig"} B), suggesting that IL-23 is not required for T cell migration across the blood--brain barrier or for Th1 cell development. In addition, the presence of Th1 cells capable of producing IFN-γ within the CNS of IL-23--deficient mice is not sufficient to induce EAE. Intracellular cytokine analysis also detected IL-6, IL-17, and TNF in the CNS-infiltrating CD4^+^ T cells from WT mice. In contrast, CD4^+^ T cells isolated from IL-23p19^−/−^ mice displayed reduced IL-6 and undetectable IL-17 production ([Fig. 1](#fig1){ref-type="fig"} B). TNF production was also markedly reduced in the IL-23p19^−/−^ cells, consistent with a previous paper suggesting that IL-23 is required for TNF production by CNS-infiltrating T cells ([@bib12]). Ex vivo analysis of draining LN (DLN) cells from immunized WT and IL-23p19^−/−^ mice reflected the CNS data, with similar IFN-γ levels, but no IL-17 production by the IL-23p19^−/−^ cells ([@bib2], [@bib14], [@bib15]). These results suggest that IL-23 is not required for Th1 development, but is essential for the development of autoantigen-specific, IL-17--producing CD4^+^ T cells.

![**T cells and inflammatory macrophages enter the CNS of MOG-immunized IL-23p19** ^−/−^ **mice.** (A) Phenotypic analysis of CNS-infiltrating cells in the brains of WT and IL-23p19^−/−^ mice at day 7 (before EAE onset) after immunization with MOG/CFA. (B) Intracellular cytokine staining of day 7 CNS-infiltrating cells from WT and IL-23p19^−/−^ mice after 18 h of stimulation with 100 μg/ml MOG peptide, all plots are gated on live CD4^+^ T cells. Data are representative of five separate experiments.](20041257f1){#fig1}

IL-23 drives an IL-17--producing T cell population
--------------------------------------------------

To confirm our in vivo data, next we cultured antigen-primed DLN cells in vitro with IL-23 to analyze cytokine production and proinflammatory gene expression. DLN cells isolated from SJL mice immunized with proteolipid protein peptide (PLP)~139-151~ were cultured in the presence of PLP, plus rIL-23, rIL-12, or medium alone. Immediately after ex vivo isolation, CD4^+^ PLP-specific IFN-γ--producing (Th1) cells and IL-17--producing (Th~IL-17~) cells were identified in the isolated DLN cells after PMA restimulation ([Fig. 2](#fig2){ref-type="fig"} A). Administration of rIL-23 promoted the expansion of Th~IL-17~ cells, and reduced the growth of Th1 cells after 5 d of culture ([Fig. 2, A and B](#fig2){ref-type="fig"}). In contrast, addition of rIL-12 promoted Th1 but reduced Th~IL-17~ growth ([Fig. 2](#fig2){ref-type="fig"} A and B). These results are consistent with papers suggesting that IL-23 is required for the development and expansion of IL-17--producing CD4^+^ T cells ([@bib2], [@bib16], [@bib17]). Both Th~IL-17~ and Th1 cells also produced TNF (Fig. S1 A, available at <http://www.jem.org/cgi/content/full/jem.20041257/DC1>) and were characterized as CD4^+^ CD62L^lo^ CD44^hi^, indicative of activated T cells; however, the Th~IL-17~ cells displayed lower CD45RB expression (Fig. S1 B). Th~IL-17~ CNS-infiltrating T cells isolated from myelin antigen-immunized mice are also CD62L^lo^ CD44^hi^ CD45RB^lo^ (unpublished data). DLN cells taken from IL-12p40^−/−^ mice, which lack both IL-12 and IL-23, could still be driven in culture with rIL-23 or rIL-12 to generate Th~IL-17~ or Th1 cells, respectively ([Fig. 2](#fig2){ref-type="fig"} C). This suggests that IL-12 and IL-23 are not required during in vivo priming for subsequent in vitro generation of IL-23 responsive Th~IL-17~ cells.

![**IL-23 promotes the expansion of IL-17 producing CD4** ^+^ **(Th~IL-17~) cells.** (A) Intracellular IL-17 and IFN-γ production by CD4^+^ DLN cells isolated from PLP-immunized WT SJL mice, either immediately after ex vivo isolation, or cultured with PLP~139-151~ peptide plus either rIL-12, rIL-23, or no added cytokine for 5 d. All plots are gated on live CD4^+^ T cells. (B) Mean percentage (±1 SD of error) of CD4^+^ T cells producing IFN-γ or IL-17 in response to 5 d of culture with IL-12 or IL-23. \*, Student\'s unpaired *t* test, P \< 0.02, averaged from eight separate experiments. (C) Intracellular IL-17 and IFN-γ production by CD4^+^ DLN cells isolated from MOG-immunized p40^−/−^ C57BL/6 either immediately after ex vivo isolation or cultured for 5 d with rIL-12 or rIL-23. All intracellular staining samples were restimulated with PMA/ionomycin for 4 h before analysis. All plots are gated on live CD4^+^ T cells and are representative of three independent experiments.](20041257f2){#fig2}

To address whether Th~IL-17~ cells can be generated in vitro from naive T cells, without in vivo priming, we isolated TCR-transgenic naive CD4^+^ T cells from DO11.10 Tg × Rag^−/−^ mice, and stimulated them with anti-CD3/anti-CD28 in the presence of rIL-12 or rIL-23. By day 7, the cultured cells were all CD62L^lo^, indicative of an activated phenotype ([Fig. 3](#fig3){ref-type="fig"} A). Upon restimulation with PMA/ionomycin, a small number of these activated T cells produced IL-17 in the IL-23--driven culture. These results suggest that a subpopulation of naive T cells can respond to IL-23 upon in vitro activation. In contrast, IL-12--driven cells produced high levels of IFN-γ and no IL-17 in vitro ([Fig. 3](#fig3){ref-type="fig"} B). The naive T cells are biased toward IFN-γ production after anti-CD3/anti-CD28 stimulation. In the absence of exogenous cytokines, a small number of T cells producing IFN-γ (∼5%) were present after anti-CD3/anti-CD28 stimulation ([Fig. 3](#fig3){ref-type="fig"} B). The same frequency of IFN-γ producers were found in the IL-23 driven cultures, suggesting that during primary in vitro stimulation, IL-23 is unable to affect IFN-γ levels. As seen with SJL DLN cultured cells, three to four rounds of in vitro IL-23 stimulation lead to reduction of IFN-γ producers (unpublished data).

![**IL-23 drives a small population of naive T cells to produce IL-17 after in vitro activation.** (A) Surface expression of CD62L on naive splenic DO11.10 × Rag^−/−^ T cells, either analyzed immediately after isolation (ex vivo) or on day 7 after in vitro anti-CD3/anti-CD28 stimulation plus IL-12 or IL-23. (B) Intracellular cytokine staining of CD4^+^ DO11.10 × Rag^−/−^ T cells on day 7 after in vitro anti-CD3/anti-CD28 stimulation plus IL-12 or IL-23. Cells were restimulated with PMA/ionomycin for 4 h before intracellular staining. (C) Naive DO11.10 × Rag^−/−^ T cells were parked in BALB/c recipients and OVA/CFA immunized. DLN cells were restimulated, PMA/ionomycin and intracellular stained for IL-17 and IFN-γ or (D) surface stained for CD44 and CD62L. All plots are gated on CD4^+^ KJ1-26^+^ cells. Results are representative of two experiments.](20041257f3){#fig3}

Next, we parked purified naive DO11.10 Tg × Rag^−/−^ CD4^+^ T cells into BALB/c hosts. After OVA~323-339~/CFA immunization, DLN cells were isolated 4 d later and analyzed immediately. A small subset of KJ1-26^+^ T cells were capable of producing IL-17 and were characterized as CD62L^lo^ and CD44^hi^ ([Fig. 3, C and D](#fig3){ref-type="fig"}). These results suggest that subcutaneous OVA~323-339~/CFA priming, which induces IL-23 expression in the DLN (not depicted) and also induces IL-17--producing T cells ([Fig. 3](#fig3){ref-type="fig"} C). Both Th1 and Th~IL-17~ cells were present in the KJ1-26^+^ OVA-primed DLN, indicating that both Th1 and Th~IL-17~ cells can be generated from naive T cells. However, it is likely that additional factors are required to enhance IL-23 responsiveness.

Gene expression pattern induced by IL-12 versus IL-23
-----------------------------------------------------

Next, we compared the gene expression profile of rIL-23-- or rIL-12--stimulated PLP-specific CD4^+^ T cells by real-time PCR to study the functional characteristics of these different cell populations. Both IL-12-- and IL-23--driven cells expressed constitutive levels of IL-12Rβ1 (unpublished data). IL-12 drives high expression of IL-12Rβ2, but little IL-23R, consistent with the ability of these cells to respond to IL-12 ([Fig. 4](#fig4){ref-type="fig"} A). IFN-γ and granzyme G expression was also significantly increased. Conversely, IL-23 drives high mRNA expression of IL-23R, but little IL-12Rβ2, consistent with the ability of these cells to respond to IL-23 ([Fig. 4](#fig4){ref-type="fig"} A). IL-17, IL-17F, IL-6, and TNF RNA levels were also significantly elevated; however, IFN-γ and granzyme G expression were dramatically reduced in the IL-23 driven cultures ([Fig. 4](#fig4){ref-type="fig"} A). Integrin-α3, which enhances cellular migration within the target organ during inflammation ([@bib18]), was also up-regulated in the IL-23--driven cells. These results suggest that the IL-23--driven T cells may play an important role in organ-specific inflammation, but not immune surveillance, via the classical IL-12--dependent IFN-γ pathway. Further analysis of \>200 lymphoid and myeloid-specific genes by real-time PCR, comparing total (lymphoid and myeloid) DLN cells cultured with rIL-23 or rIL-12 showed that ∼80% of the genes displayed comparable expression profiles ([Fig. 4](#fig4){ref-type="fig"} B). Of the remaining genes showing divergence, IL-12 elevated expression of many host defense genes such as granzyme F, granzyme G, TRAIL, BLYS, IFN-γ, TRAIL R2, and FASL. However, IL-23 induced, in addition to IL-17 and IL-17F, elevated expression of genes such as CCL7, CCL17, CCL20, CCL22, CCR1, and GM-CSF. We are currently characterizing the molecular basis of the cellular responses to IL-12 versus IL-23 by microarray analysis. Preliminary data identifies that IL-12 specifically induced 306 genes (greater than fivefold), comprised of many cytotoxicity and host defense genes. In contrast, IL-23 specifically induced 162 genes (greater than fivefold), including numerous novel expression sequence tags with unknown functions in addition to a 34-fold increase of IL-17 (unpublished data). Together, these results suggest that IL-12, not IL-23, drives development of T cell--expressing host defense genes. The precise in vivo function of IL-23 is currently unclear. Its capacity to induce IL-17 and other proinflammatory factors appears important for neutrophil recruitment ([@bib17]) and granuloma formation ([@bib19]). However, when dysregulated, it causes inflammatory responses often associated with autoimmunity.

![**Gene expression analysis of IL-23 versus IL-12 driven T cells.** (A) Quantitative analysis of mRNA expression levels of selected genes, comparing sorted CD4^+^ DLN cells isolated from PLP-immunized mice, either not cultured (ex vivo) or cultured with rIL-23 or rIL-12 for 10 d. (B) Quantitative analysis of mRNA expression levels of \>200 selected genes, comparing total DLN cells isolated from PLP-immunized mice, cultured with either rIL-23 or rIL-12 for 10 d. All samples were activated with PMA/ionomycin for 4 h before RNA extraction and Taqman analysis. Results are normalized to a housekeeping gene, ubiquitin, and representative of two similar experiments.](20041257f4){#fig4}

Th~IL-17~ cells are highly encephalogenic
-----------------------------------------

To compare the capacity of Th1 versus Th~IL-17~ cells to induce EAE pathology, we transferred IL-23-- or IL-12--expanded PLP-specific cells to naive recipient mice. To confirm that both IL-23-- and IL-12--cultured cells were viable in vivo and could cross the blood--brain barrier, cells were fluorescently labeled before passive transfer. 3 d after transfer, similar frequencies of labeled cells were detected in the blood, spleen, and CNS, regardless of whether they were cultured with IL-23 or IL-12, suggesting both Th1 and Th~IL-17~ cells can survive in vivo and traffic to the CNS. In addition, the transferred cells also remained stable with respect to their IFN-γ or IL-17 production in vivo ([Fig. 5](#fig5){ref-type="fig"} A). Labeled cells were still detectable 6 d after transfer, but with decreased mean fluorescence intensity in both groups, indicative of normal proliferation/division of the cells (unpublished data).

![**IL-17--producing Th~IL-17~ cells induce EAE.** (A) PLP-primed DLN cells cultured with rIL-23 or rIL-12 for 10 d, labeled with CFSE (peak MFI = 4,654) and transferred (5 × 10^6^ cells/mouse) into recipient WT SJL mice. Cells were tracked at day 3 after immunization, with further gating on splenic CFSE^+^ CD4^+^ cells to determine IFN-γ and IL-17 production by intracellular staining. (B) PLP-primed DLN cells cultured with either rIL-23 (squares) or rIL-12 (triangles) for 10 d, and transferred into WT SJL mice as either purified CD4^+^ cells (3 × 10^6^ cells/mouse; *n* = 10/group; top), or as total DLN cells (7 × 10^6^ cells/mouse; *n* = 3/group; bottom), with mean EAE scores recorded. (C) Mean EAE scores of WT recipient mice (*n* = 5/group) passively transferred with graded numbers of Th~IL-17~ cells: 1.2 × 10^6^ Th~IL-17~ (closed squares), 3 × 10^5^ Th~IL-17~ (closed triangles), 1.5 × 10^5^ Th~IL-17~ (open circles), or 2.0 × 10^4^ Th~IL-17~ (open diamonds). Results are summarized from two separate experiments. (D) Mean EAE scores of WT recipient mice (*n* = 5/group) passively transferred with either 5 × 10^5^ Th~IL-17~ cells (open squares), 5 × 10^5^ Th1 cells (open diamonds), or cotransferred with Th~IL-17~ plus Th1 cells (5 × 10^5^ of each; closed triangles), or Th~IL-17~ plus sorted IFN-γ^−^ cells (5 × 10^5^ Th~IL-17~ plus 2 × 10^5^ IFN-γ^−^ cells; closed circles). (C--D) Th~IL-17~ cell numbers are calculated from intracellular cytokine staining analysis, with ∼3-5 × 10^6^ total DLN cells passively transferred per recipient mouse.](20041257f5){#fig5}

Next, we determined the encephalogenicity of Th~IL-17~ versus Th1 cell populations. Mice that received either IL-23--driven Th~IL-17~ cells (either as purified CD4^+^ T cells or total DLN containing ∼3 × 10^5^ Th~IL-17~ cells) showed severe clinical signs of EAE ([Fig. 5](#fig5){ref-type="fig"} B). However, mice that received an equivalent number of IL-12--driven Th1 cells showed no clinical signs of EAE, suggesting that Th1 cells are less efficient at inducing EAE ([Fig. 5](#fig5){ref-type="fig"} B). When graded numbers of Th~IL-17~ were transferred into naive SJL mice, Th~IL-17~ cell number directly correlated with disease severity, regardless of the number of Th1 cells present ([Fig. 5](#fig5){ref-type="fig"} C). To determine whether the IFN-γ^−^ cells might negatively regulate EAE, next we cotransferred FACS-sorted IFN-γ^−^ cell population or Th1 cells with Th~IL-17~ cells to recipient mice. Neither IFN-γ^−^ cells nor Th1 cells could reduce the Th~IL-17~-mediated EAE pathology ([Fig. 5](#fig5){ref-type="fig"} D), suggesting that the inability of Th1 cells to induce EAE was not due to regulatory components in the IL-12--driven cultures. In addition, we noted that short-term IL-12--driven cell populations (7 d) could contain a small number of contaminating IL-17--producing cells that can induce mild EAE ([Fig. 5](#fig5){ref-type="fig"} D). These results demonstrate that IL-17--producing T cells are more pathogenic than IFN-γ--producing T cells.

To test whether IL-17 production directly contributes to EAE severity, PLP-immunized WT SJL mice were treated with neutralizing antibodies against IL-17 ([Fig. 6](#fig6){ref-type="fig"} A). Anti--IL-17 treatment resulted in partial protection from EAE, consistent with a recent paper suggesting that IL-17--deficient mice are resistant to actively induced EAE and CIA ([@bib20]), and confirming that the IL-23--IL-17 pathway is important in inflammatory autoimmune diseases. However, the observed partial protection indicates that other factors induced by IL-23, including IL-6, IL-17F, and TNF, are also important in EAE pathogenesis. Indeed, the highly intense disease induced by passive transfer of Th~IL-17~ cells (3--5 × 10^5^ cells/recipient) cannot be blocked by anti--IL-17 antibody treatment of recipient mice (unpublished data), suggesting that multiple factors produced by these exceptionally pathogenic Th~IL-17~ cells must be neutralized before inhibiting their actions. In addition, IL-17 may also have a role in the initial expansion of the Th~IL-17~ cells as suggested by a recent paper showing a role for IL-17 during immune priming ([@bib21]). It was previously unclear whether the classical Th1-type/IFN-γ--mediated immune response is essential for induction or maintenance of autoimmune disease. Treatments with IFN-γ lead to disease exacerbation in human MS ([@bib22]), and transgenic mice overexpressing IFN-γ in the CNS showed increased oligodendrocyte death leading to demyelinating diseases ([@bib23], [@bib24]). However, despite the potential toxic effects of IFN-γ in the CNS, mice that lack critical components of the Th1--IFN-γ pathway are highly susceptible to EAE ([@bib8]--[@bib12]). Consistent with this, treatment of PLP-immunized mice with neutralizing antibodies against IFN-γ demonstrated intensified disease leading to \>75% mortality ([Fig. 6](#fig6){ref-type="fig"} B), indicating that loss of IFN-γ results in disease exacerbation.

![**IL-17, not IFN-**γ**, contributes to EAE severity.** (A) WT SJL mice actively immunized with PLP emulsified in CFA, and treated at day 7 with 200 μg anti--IL-17 (closed diamonds) or isotype control (open diamonds), *n* = 5/group. (B) WT SJL mice actively immunized with PLP emulsified in CFA (using suboptimal immunization strategy to give weaker disease), and treated at days 0 and 7 with 200 μg anti--IFN-γ (closed squares) or isotype control (open squares), *n* = 7/group. Plots are representative of three similar experiments.](20041257f6){#fig6}

Discussion
==========

In this paper, we have identified a pathogenic T cell population critical for autoimmune inflammation. This IL-23--mediated immune response is not associated with IFN-γ or IL-4 production. IL-23 promotes the development and expansion of activated CD4^+^ cells that produce IL-17, IL-17F, IL-6, and TNF upon antigen-specific stimulation. Genetic analysis of these Th~IL-17~ cells identified a unique expression pattern of proinflammatory cytokines and other novel factors. This data, plus the observation that IFN-γ--producing cells, are present in EAE-resistant, IL-23--deficient mice, suggesting that the IL-23--driven immune response is independent of the IFN-γ--Th1 pathway. IL-17 production was undetectable in CD4^+^ T cells from IL-23--deficient mice (derived from either CNS or LN), suggesting that IL-23 is essential for the development of autoantigen-specific T cell production of IL-17. By in vitro expansion of antigen-primed DLN cells with rIL-23 and passive transfer studies, we confirm that these IL-23--dependent T cells are highly pathogenic, and essential for the establishment of organ-specific inflammation associated with autoimmunity.

In key published EAE passive transfer papers ([@bib25], [@bib26]), PLP-primed DLN cells were cultured with rIL-12 for 4 d before transfer of 20--30 × 10^6^ cells into recipient mice. Both Th1 and Th~IL-17~ cells can be found in antigen-primed DLN cells immediately after isolation; however, they reduce over time when cultured with IL-23 or IL-12, respectively. 4 d in the presence of rIL-12 is not sufficient time for the complete loss of IL-17 production; therefore, the cells were cultured for 10--14 d with either IL-12 or IL-23 before passive transfer. Our data indicates that the Th~IL-17~ cells are far more efficient than Th1 cells at inducing EAE; as a result, we transferred ∼10-fold fewer cells in comparison to the published reports.

A recent paper demonstrated that antigen-primed IFN-γ^+^ versus IFN-γ^−^ cells have differential in vivo survival potentials ([@bib27]). The IFN-γ^+^ cells were short-lived and performed immediate effector functions, whereas the IFN-γ^−^ cells had increased durability and possessed long-term memory function. This is consistent with our work demonstrating the existence of an IFN-γ^−^ IL-17^+^--producing T cell population. In addition, some but not all IFN-γ^−^ cells could produce IFN-γ at a later stage after strong antigenic stimulation in the presence of IL-12 ([@bib27]), suggesting a shared a precursor lineage. In our studies, antigen-primed activated T cells are responsive to both IL-12 and IL-23. In short-term in vitro assays, CD62L^hi^ naive T cells appear to predominately respond to IL-12 and are biased toward IFN-γ production after anti-CD3 and anti-CD28 stimulation ([Fig. 3, A and B](#fig3){ref-type="fig"}, and reference [@bib3]). In vitro activation of naive T cells in the presence of IL-23 could induce the generation of a small population of IL-17--producing T cells; however, during this short-term culture, IL-23 was unable to affect residual IFN-γ production. It is likely that during in vivo activation of naive T cells, an array of cytokines and cellular interactions are required to optimally induce IL-23 responsiveness. For example, naive T cells from autoimmune-prone DBA-1 mice can be driven to produce IL-17 when alternatively stimulated via ICOS ([@bib28]).

The in vivo function of IL-23 remains to be determined, but appears to be clearly associated with IL-17, IL-17F, IL-6, and TNF production. IL-17 is an important effector cytokine during inflammation. IL-17--deficient mice are resistant to CIA and EAE ([@bib20]), and therapeutic treatment with an IL-17 antagonist antibody can reverse ongoing CIA ([@bib29]), consistent with the notion that IL-17 functions during the effector phase of an inflammatory response. In addition, IL-17 has been found in many human autoimmune diseases, including multiple sclerosis ([@bib30]), rheumatoid arthritis ([@bib31]), and psoriasis ([@bib32]). IL-17--producing T cells have also been identified in the synovial fluid of patients with Lyme arthritis ([@bib33]), suggesting involvement of IL-17 in infection-induced immunopathology. IL-17 receptors that bind both IL-17 and IL-17F are ubiquitously expressed in a broad range of cell types including myeloid and endothelial cells. Engagement of IL-17 and/or IL-17F on these cell types promotes expression of IL-1, IL-6, IL-8, TNF, and ICAM-1, which are all critical factors that drive inflammation ([@bib34]).

IL-6 is predominately produced by myeloid cells and is an important factor promoting inflammatory responses. The production of IL-6 by Th~IL-17~ but not Th1 cells is intriguing and may explain the hyperencephalogenicity of Th~IL-17~ cells. IL-6 produced by LPS-activated dendritic cells can turn off regulatory T cell (T reg cell) function, allowing effector T cell activation ([@bib35]). It is tempting to speculate that in the absence of microbe-activated dendritic cells, the IL-6--producing Th~IL-17~ cells may have the potential to directly inhibit the action of T reg cell function within the target organ during autoimmune inflammation. The role of TNF in chronic inflammatory diseases is well recognized ([@bib36]). Interestingly, TNF is produced by both Th1 and Th~IL-17~ cells after in vitro stimulation, suggesting that TNF may play a role in both IL-12 and IL-23 linked immune responses. Thus, the cellular mechanism of action of IL-23 in autoimmunity is the expansion of self-reactive IL-17, IL-17F, TNF, and IL-6--producing T cells. Importantly, this IL-23--mediated immune response has a different gene expression pattern than IL-12--driven T cell responses. Understanding the molecular basis for the differential gene expression pattern of the IL-23--dependent T cell population could provide additional therapeutic targets for the treatment of inflammatory autoimmune diseases.

Materials and Methods
=====================

Mice
----

IL-23p19^−/−^ (IL-23--deficient mice) and their WT controls were generated on a mixed B6 × 129 background using approaches described previously ([@bib1]).

SJL/J and IL-12p40--deficient (p40^−/−^ C57BL/6) mice were obtained from The Jackson Laboratory. All animal procedures were approved by the DNAX IACUC committee, in accordance with AAALAC guidelines.

EAE
---

EAE was induced in female mice at 8--12 wk and clinically assessed as described previously ([@bib1]), using 100 μg MOG~35-55~ per mouse for B6 × 129 and C57BL/6 strains, or 80 μg PLP~139-151~ (PLP) per mouse for SJL strains and emulsified in CFA. Where required, brain- and spinal cord--infiltrating cells were isolated from MOG-immunized WT and IL-23p19^−/−^ mice at day 7 (before EAE onset; reference [@bib1]), and cultured with 100 μg/ml MOG for 18 h (plus Golgi-Plug for final 4 h) before intracellular cytokine staining.

Intracellular cytokine flow cytometry.
--------------------------------------

Cells were surface stained with anti--CD4-FITC in the presence of Fc blocking antibodies. Cells were washed, fixed, permeabilized with Cytofix/Cytoperm buffer and intracellular stained with antibodies against IFN-γ/TNF/IL-17/IL-6/IL-4, and analyzed with a FACScalibur flow cytometer. For DLN and naive T cell intracellular cytokine staining, samples were restimulated with 50 ng/ml PMA and 500 ng/ml ionomycin (Sigma-Aldrich) in the presence of Golgi-plug for 4 h, before surface staining with combinations of antibodies against CD4/CD45RB/CD62L/CD44 and intracellular cytokine staining with combinations of antibodies against IFN-γ/IL-17/TNF/IL-4. All antibodies and staining buffers were purchased from BD Biosciences.

DLN cultures and passive transfer
---------------------------------

Inguinal, axillary, and branchial LNs were harvested from SJL mice 9 d after antigen immunization. DLN cells were cultured in complete RPMI 1640 media containing 10% FCS, supplemented with Pen-Strep, [l]{.smallcaps}-glutamine, Hepes, sodium pyruvate, and 2-ME, in the presence of 20 μg/ml PLP~139-151~ for an initial 5 d, plus addition of either 10 ng/ml rIL-12 or 10 ng/ml rIL-23. Media was replaced on days 5 and 8 and supplemented with 2 ng/ml IL-2 (BD Biosciences), plus rIL-23 or rIL-12. At day 5, cells initially cultured with IL-12 were rested without IL-12 for 3 d to prevent excessive apoptosis. As required, day 10 cultured DLN cells were positively selected and enriched using CD4^+^ microbeads (Miltenyi Biotec) with \>95% purity. For passive transfer, SJL DLN cells (either total DLN or CD4^+^ MACS enriched) were harvested, washed in RPMI 1640, and injected i.v. into naive WT female SJL mice (see [Fig. 5](#fig5){ref-type="fig"} for culture conditions and cell number in each experiment). The frequency of Th~IL-17~ and Th1 cells was calculated by intracellular flow cytometry performed in parallel for each sample. For IL-12p40^−/−^ cultures, DLN cells were harvested from p40^−/−^ mice at day 9 after MOG immunization and cultured with 100 μg/ml MOG~35-55~ peptide plus 10 ng/ml rIL-12 or 10 ng/ml rIL-23 for 5 d before analysis.

Naive T cell cultures and adoptive transfer.
--------------------------------------------

DLN and spleen cells were isolated from naive DO11.10 Tg × Rag^−/−^ mice, and CD4^+^ cells were purified by MACS. For culture, 10^6^ naive CD4^+^ spleen cells/ml were activated for 3 d with 10 μg/ml of plate-bound anti-CD3 and 1 μg/ml anti-CD28 with 10 ng/ml rIL-12 or 10 ng/ml rIL-23. Cultured cells were rested for 4 d before restimulation with PMA/ionomycin in the presence of Golgi-plug for intracellular cytokine staining on day 7. For adoptive transfer, pooled naive CD4^+^ MACS-purified spleen and LN cells from DO11.10 Tg × Rag^−/−^ mice were pooled and injected into recipient BALB/c mice, with each mouse receiving ∼5 × 10^6^ CD4^+^ KJ1-26^+^ cells. Recipient mice were immunized with 20 μg OVA~323-339~ peptide emulsified in CFA on day 2, and the DLN cells were harvested on day 6 and immediately analyzed for intracellular cytokine staining after PMA/ionomycin restimulation. Where required, cells were surface stained with combinations of fluorescently labeled antibodies KJ1-26, CD4, CD62L, and CD44.

Gene expression analysis.
-------------------------

RNA was extracted from DLN cells isolated from naive SJL non--PLP-primed control mice (unprimed), and as total DLN or CD4^+^ MACS-enriched cells from PLP-immunized mice. These cells were either not cultured (ex vivo) or cultured with rIL-23 or rIL-12 for 10 d. All samples were activated with 50 ng/ml PMA and 500 ng/ml ionomycin (Sigma-Aldrich) for 4 h before cDNA preparation. mRNA expression was quantitated by real-time PCR as described previously ([@bib2]).

Fluorescent dye staining and tracking.
--------------------------------------

SJL DLN cells cultured for 10 d with either IL-23 or IL-12 were labeled with CFSE (Molecular Probes), transferred i.v. into naive recipient mice (5 × 10^6^ total cells/mouse). At day 3 after transfer, spleens were removed and homogenized, red blood cells were lysed, and mononuclear cells were surface stained with anti--CD4-APC and intracellular stained with anti--IL-17 or anti--IFN-γ as described before. Blood was collected and lysed (RBC lysis buffer; Sigma-Aldrich), and mononuclear cells from brains and spinal cord tissue were prepared as described previously ([@bib1]) and surface stained with anti--CD4-APC.

Sorting of IFN-γ^+^ and IFN-**γ** DLN cells
-------------------------------------------

IFN-γ^+^ and IFN-γ^−^ cells were sorted from PLP-primed SJL DLN cells cultured with rIL-12 for 10 d, after 3 h stimulation with anti-CD3/anti-CD28, using anti-CD45 anti--IFN-γ bispecific antibody-capture matrix kit (Miltenyi Biotec) as described previously ([@bib27]).

Antibody treatment of EAE.
--------------------------

WT SJL mice were treated with 200 μg i.p anti--IL-17 (clone 18H10, rat IgG1), or treated with anti--IFN-γ (clone XMG1.2, rat IgG1) or relevant isotype controls, immunized with PLP~139-151~ as described before. Both neutralizing antibodies were generated at DNAX (with \<4 EU/mg of mAb); however, they are also commercially available from BD Biosciences, Southern Biotechnology Associates, Inc., and Upstate Biotechnology.

Online supplemental material
----------------------------

Fig. S1 demonstrates that both Th~IL-17~ and Th1 cells produce TNF, but not IL-4, and are phenotypically characterized as CD4^+^CD44^hi^CD62L^lo^ indicative of activated T cells. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20041257/DC1>.
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